22 research outputs found
Previous published studies which evaluated EBNA-1 by IHC on breast cancer specimens.
*<p>IHC was done on EBV-DNA PCR positive samples only.</p
Immunohistochemical detection of EBNA-1 in breast tissue specimens.
<p>A. Tumor cells (infiltrating ductal carcinoma) showing intense granular nuclear positivity for EBNA-1 antibody. B. Benign breast tissue negative for EBNA-1; C. Positive control (nasopharyngeal carcinoma tumor cells showing nuclear positivity for EBNA-1) slide; D. Negative control (no signal is seen in infiltrating ductal carcinoma cells without application of primary antibody). All photographs and in 400x original magnification.</p
Demographic, reproductive and tumor severity amongst cases (n = 51) with positive or negative IHC.
<p>All values indicate mean (standard deviation) unless stated otherwise.</p>*<p>Number (percentage).</p
Baseline characteristics between those with benign and malignant lesions.
<p>All values indicate mean (standard deviation) unless stated otherwise.</p>*<p>Number (percentage).</p>†<p>In those with one or more conceptions.</p
Box plot showing anti-EBNA-1 IgG antibody levels in women with benign and malignant breast disease, stratified by age.
<p>The central horizontal line in the box indicates the median value, edges of the box indicate inter-quartile range, and the whiskers indicate values at 5<sup>th</sup> and 95<sup>th</sup> percentiles. The values at the bottom of the box indicate the number of women in whom serology was done, out of the total number of eligible women in particular category. The mean IgG levels in 25 to 45 year age group were significantly higher in women with malignant breast disease (48.15; SD 47.38 IU/ml) as compared to those with benign breast disease (17.37; SD 16.89 IU/mL) (p = 0.01).</p
A Young Medical Trainee Examines a Patient with Pulmonary TB at a Rural Hospital in India
<p>In such low-income countries, more years of clinical training and greater exposure to TB patients are important risk factors for acquiring new TB infection.</p
Receiver Operating Characteristics (ROC) curves for all clinical sites for detection of anaemia at haemoglobin cutoff points (a) 7 g/dL and (b) 9 g/dL.
<p>Receiver Operating Characteristics (ROC) curves for all clinical sites for detection of anaemia at haemoglobin cutoff points (a) 7 g/dL and (b) 9 g/dL.</p
Sample Study Profile, tongue pallor as index test and haemoglobin levels (less than 7 g/dL and 9 g/dL) as reference standards.
<p>Sample Study Profile, tongue pallor as index test and haemoglobin levels (less than 7 g/dL and 9 g/dL) as reference standards.</p
Interobserver variability in assessment of anaemia (n = 128).
<p>Interobserver variability in assessment of anaemia (n = 128).</p